Depomed Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
DepoMed Inc (DEPO) PT Lowered to $9 at Piper Jaffray
August 8, 2017 8:23 AM EDTPiper Jaffray lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $9.00 (from $10.00) while maintaining a Neutral rating following Q2 results and another downward guide.
"Notably, DEPO cut its 2017 revenue and EBITDA guidance ranges once again, driven in part by continued headwinds... More
Depomed (DEPO) Misses Q2 EPS by 1c, Trims FY Guidance
August 7, 2017 4:03 PM EDTDepomed (NASDAQ: DEPO) reported Q2 EPS of $0.08, $0.01 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $100 million versus the consensus estimate of $99.42 million.
GUIDANCE:
Depomed sees FY2017 revenue of $395-410 million, versus the consensus of $416.3... More
